What are the most valued startups in the telemedicine market?
Download our beautiful pitch about the telemedicine market

In our updated market reports, you will find everything you need
The telemedicine market now includes large public platforms, specialized virtual clinics, care infrastructure providers, and focused digital health services.
We update this ranking every month to reflect new funding rounds, public market movements, acquisitions, and revised valuation estimates.
The database currently covers 84 telemedicine companies with a combined midpoint valuation of approximately $65.1 billion.
And if you want to better understand this new industry, you can download our pitch covering the telemedicine market.
A quick summary table
| Metric | Value |
|---|---|
| Most valuable telemedicine startup | Hims & Hers, $8.1B |
| Second most valuable telemedicine startup | Ro, $5.5B–$7.5B |
| Median telemedicine company valuation | Approximately $275M |
| Share of telemedicine valuation captured by the top 10 | Approximately 56.2% |
| Top telemedicine valuation vs. median | Approximately 29.5 times |
| Median telemedicine valuation-to-capital-raised ratio | Approximately 2.8 times |
| Telemedicine startups valued at $1B+ | 19 based on midpoint valuations |
Top startups in the telemedicine market ranked by valuation
Here is an updated table that ranks the top startups in the telemedicine market based on their latest reported or estimated valuations.
If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the telemedicine market.
| # | Startup Name | What They Do | Current Valuation ($) | Valuation Confidence Level | Valuation Type | Evidence Status | Total Funding ($) | Funding Confidence Level |
|---|---|---|---|---|---|---|---|---|
| 1 | Hims & Hers | Consumer telehealth and wellness | $8.1B | Full Confidence | Public Market Cap | Observed | $477M | Strong Confidence |
| 2 | Ro | Direct-to-patient virtual care | $5.5B–$7.5B | Partial Confidence | Comparables-Based Estimate | Estimated | $1.0B | Strong Confidence |
| 3 | Lyra Health | Employer mental health benefits | $4.8B–$5.8B | Strong Confidence | Comparables-Based Estimate | Estimated | $915M | Strong Confidence |
| 4 | Sword Health | AI virtual MSK care | $3.6B–$4.4B | Strong Confidence | Announced Private Round Valuation | Estimated | $365M | Strong Confidence |
| 5 | Headspace Health | Digital mental health platform | $2.3B–$3.0B | Strong Confidence | Revenue or ARR Multiple Estimate | Estimated | $124M | Partial Confidence |
| 6 | Alma | Therapist practice enablement platform | $1.8B–$2.8B | Partial Confidence | Acquisition Value | Estimated | $221M | Strong Confidence |
| 7 | MDLive | 24/7 virtual care | $2.0B | Full Confidence | Acquisition Value | Observed | $174M | Partial Confidence |
| 8 | eMed | Employer metabolic health platform | $2.0B | Full Confidence | Announced Private Round Valuation | Observed | $200M | Partial Confidence |
| 9 | Kry | European digital doctor visits | $1.7B–$2.2B | Partial Confidence | Comparables-Based Estimate | Estimated | $711M | Strong Confidence |
| 10 | Talkiatry | Insurance-covered virtual psychiatry | $1.5B–$2.1B | Strong Confidence | Implied Valuation from Raise | Implied | $377M | Partial Confidence |
| 11 | Maven Clinic | Women’s virtual health clinic | $1.5B–$1.9B | Strong Confidence | Announced Private Round Valuation | Estimated | $425M | Partial Confidence |
| 12 | Teladoc Health | Public telehealth provider | $1.6B | Full Confidence | Public Market Cap | Observed | $244M | Strong Confidence |
| 13 | Charlie Health | Virtual intensive mental-health treatment | $1.3B–$1.8B | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $404M | Low Confidence |
| 14 | Cadence | Remote chronic care platform | $1.2B | Full Confidence | Announced Private Round Valuation | Observed | $241M | Full Confidence |
| 15 | Eucalyptus | Consumer digital health clinics | $1.2B | Strong Confidence | Acquisition Value | Observed | $120M | Strong Confidence |
| 16 | SonderMind | Therapy marketplace and platform | $1.0B–$1.4B | Partial Confidence | Comparables-Based Estimate | Estimated | $183M | Strong Confidence |
| 17 | Doctor On Demand | Virtual primary care visits | $900M–$1.3B | Partial Confidence | Proxy-Based Estimate | Estimated | $239M | Strong Confidence |
| 18 | Rula | Therapist network and care access | $850M–$1.2B | Partial Confidence | Implied Valuation from Raise | Implied | $263M | Partial Confidence |
| 19 | Midi Health | Virtual midlife women’s care | $1.0B | Full Confidence | Announced Private Round Valuation | Observed | $252M | Full Confidence |
| 20 | Talkspace | Public online therapy platform | $870M | Full Confidence | Public Market Cap | Observed | $359M | Strong Confidence |
| 21 | Ginger | On-demand mental healthcare platform | $700M–$1.0B | Low Confidence | Acquisition Value | Estimated | $213M | Strong Confidence |
| 22 | Genome Medical | Virtual genetic care services | $550M–$750M | Partial Confidence | Implied Valuation from Raise | Implied | $195M | Strong Confidence |
| 23 | Wheel | Virtual care infrastructure | $500M–$800M | Partial Confidence | Implied Valuation from Raise | Estimated | $216M | Full Confidence |
| 24 | TimelyCare | Student virtual health platform | $450M–$700M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $60M | Strong Confidence |
| 25 | Electronic Caregiver | AI-enabled remote elder care | $490M–$600M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $110M | Partial Confidence |
| 26 | Brightline | Pediatric behavioral healthcare | $400M–$650M | Low Confidence | Comparables-Based Estimate | Estimated | $205M | Partial Confidence |
| 27 | Vida Health | Virtual chronic care | $400M–$700M | Partial Confidence | Implied Valuation from Raise | Estimated | $163M | Full Confidence |
| 28 | TytoCare | Remote home medical examinations | $400M–$550M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $205M | Strong Confidence |
| 29 | HealthHero | European digital healthcare platform | $400M–$550M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $15M | Low Confidence |
| 30 | MD Integrations | White-label physician telehealth network | $390M–$510M | Strong Confidence | Implied Valuation from Raise | Implied | $77M | Strong Confidence |
| 31 | Equip | Virtual eating-disorder treatment | $360M–$520M | Partial Confidence | Implied Valuation from Raise | Implied | $164M | Strong Confidence |
| 32 | Thirty Madison | Chronic-condition digital care | $500M | Full Confidence | Acquisition Value | Observed | $210M | Full Confidence |
| 33 | PlushCare | Virtual primary and mental care | $450M | Full Confidence | Acquisition Value | Observed | $31M | Strong Confidence |
| 34 | Lemonaid Health | Consumer telehealth and pharmacy services | $400M | Full Confidence | Acquisition Value | Observed | $55M | Strong Confidence |
| 35 | Ada Health | AI symptom assessment platform | $320M–$450M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $167M | Full Confidence |
| 36 | Tava Health | Employer mental health platform | $270M–$500M | Strong Confidence | Implied Valuation from Raise | Implied | $73M | Full Confidence |
| 37 | Pelago | Virtual substance-use disorder care | $300M–$450M | Partial Confidence | Implied Valuation from Raise | Implied | $151M | Partial Confidence |
| 38 | Doctor Anywhere | Southeast Asian virtual healthcare | $280M–$420M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $176M | Full Confidence |
| 39 | Pager | Enterprise care navigation platform | $250M–$400M | Low Confidence | Comparables-Based Estimate | Estimated | $111M | Partial Confidence |
| 40 | GetHarley | Virtual skincare consultation marketplace | $240M–$400M | Partial Confidence | Implied Valuation from Raise | Estimated | $67M | Strong Confidence |
| 41 | Hazel Health | School-based pediatric virtual care | $250M–$380M | Partial Confidence | Implied Valuation from Raise | Implied | $113M | Strong Confidence |
| 42 | Brightside Health | Online mental healthcare services | $240M–$340M | Partial Confidence | Implied Valuation from Raise | Implied | $108M | Strong Confidence |
| 43 | Maple | Canadian virtual care platform | $200M–$320M | Partial Confidence | Comparables-Based Estimate | Estimated | $72M | Strong Confidence |
| 44 | Eleanor Health | Value-based addiction and mental care | $190M–$310M | Partial Confidence | Implied Valuation from Raise | Implied | $166M | Partial Confidence |
| 45 | Avi Medical | Hybrid primary care clinics | $180M–$300M | Low Confidence | Comparables-Based Estimate | Estimated | $89M | Strong Confidence |
| 46 | Altibbi | MENA virtual medical consultations | $180M–$300M | Partial Confidence | Implied Valuation from Raise | Estimated | $53M | Strong Confidence |
| 47 | Recuro Health | Virtual-first healthcare benefit platform | $180M–$280M | Partial Confidence | Implied Valuation from Raise | Estimated | $89M | Partial Confidence |
| 48 | Summus Global | Virtual specialist medical consultations | $210M–$240M | Strong Confidence | Implied Valuation from Raise | Implied | $91M | Partial Confidence |
| 49 | Oshi Health | Virtual digestive healthcare | $180M–$240M | Partial Confidence | Comparables-Based Estimate | Estimated | $113M | Full Confidence |
| 50 | Heal | In-home primary healthcare | $150M–$250M | Low Confidence | Acquisition Value | Estimated | $174M | Partial Confidence |
| 51 | MedArrive | In-home virtual care delivery | $160M–$230M | Partial Confidence | Comparables-Based Estimate | Estimated | $41M | Partial Confidence |
| 52 | Boulder Care | Virtual addiction treatment | $160M–$220M | Strong Confidence | Comparables-Based Estimate | Estimated | $85M | Strong Confidence |
| 53 | Form Health | Virtual obesity medical care | $160M–$220M | Strong Confidence | Revenue or ARR Multiple Estimate | Estimated | $70M | Partial Confidence |
| 54 | Array Behavioral Care | Virtual behavioral health provider | $150M–$230M | Partial Confidence | Implied Valuation from Raise | Estimated | $49M | Strong Confidence |
| 55 | Quartet Health | Behavioral care coordination platform | $120M–$250M | Low Confidence | Acquisition Value | Estimated | $266M | Partial Confidence |
| 56 | Ophelia | Virtual opioid-use disorder treatment | $140M–$220M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $68M | Strong Confidence |
| 57 | Nurx | Women’s digital healthcare services | $130M–$220M | Low Confidence | Proxy-Based Estimate | Estimated | $96M | Partial Confidence |
| 58 | eVisit | Health-system telehealth software | $130M–$220M | Partial Confidence | Comparables-Based Estimate | Estimated | $72M | Strong Confidence |
| 59 | Meru Health | Digital mental health treatment | $140M–$200M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $42M | Partial Confidence |
| 60 | Sesame | Cash-pay healthcare marketplace | $130M–$200M | Partial Confidence | Comparables-Based Estimate | Estimated | $85M | Strong Confidence |
| 61 | Allara Health | Virtual hormonal healthcare | $130M–$165M | Strong Confidence | Announced Private Round Valuation | Observed | $39M | Full Confidence |
| 62 | Amwell | Enterprise telehealth platform | $144M | Full Confidence | Public Market Cap | Observed | $1.5B | Partial Confidence |
| 63 | FOLX Health | LGBTQIA+ virtual healthcare | $120M–$200M | Partial Confidence | Comparables-Based Estimate | Estimated | $59M | Full Confidence |
| 64 | Quyi Network | Chinese internet healthcare platform | $110M–$190M | Low Confidence | Comparables-Based Estimate | Estimated | $84M | Partial Confidence |
| 65 | Firefly Health | Virtual-first primary care | $100M–$180M | Partial Confidence | Comparables-Based Estimate | Estimated | $50M | Full Confidence |
| 66 | Nice Healthcare | Employer virtual primary care | $100M–$180M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $42M | Strong Confidence |
| 67 | Curai Health | AI-assisted virtual primary care | $90M–$160M | Low Confidence | Comparables-Based Estimate | Estimated | $57M | Strong Confidence |
| 68 | Antidote Health | Virtual primary care and insurance | $90M–$140M | Partial Confidence | Implied Valuation from Raise | Estimated | $34M | Full Confidence |
| 69 | Workit Health | Virtual addiction treatment platform | $90M–$140M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $131M | Partial Confidence |
| 70 | MORE Health | Virtual medical second opinions | $70M–$140M | Low Confidence | Proxy-Based Estimate | Estimated | $78M | Partial Confidence |
| 71 | 98point6 | Text-based primary care | $80M–$120M | Partial Confidence | Acquisition Value | Estimated | $305M | Partial Confidence |
| 72 | HealthTap | On-demand virtual primary care | $70M–$120M | Low Confidence | Proxy-Based Estimate | Estimated | $38M | Full Confidence |
| 73 | Medici | Secure clinician-patient messaging | $60M–$120M | Low Confidence | Proxy-Based Estimate | Estimated | $70M | Partial Confidence |
| 74 | First Stop Health | Employer virtual healthcare | $65M–$125M | Low Confidence | Comparables-Based Estimate | Estimated | $13M | Low Confidence |
| 75 | CirrusMD | Chat-first virtual care | $50M–$90M | Low Confidence | Acquisition Value | Estimated | $48M | Partial Confidence |
| 76 | Mantra Health | College mental-health services | $55M–$85M | Partial Confidence | Comparables-Based Estimate | Estimated | $32M | Strong Confidence |
| 77 | Chunyu Yisheng | Online doctor consultations | $40M–$55M | Strong Confidence | Acquisition Value | Observed | $244M | Partial Confidence |
| 78 | Mindbloom | At-home ketamine therapy | $35M–$65M | Low Confidence | Proxy-Based Estimate | Estimated | $0M | Low Confidence |
| 79 | Monument | Online alcohol-use disorder treatment | $35M–$50M | Partial Confidence | Comparables-Based Estimate | Estimated | $24M | Strong Confidence |
| 80 | Doctor Care Anywhere | Online GP and diagnostics | $35M | Full Confidence | Public Market Cap | Observed | $75M | Partial Confidence |
| 81 | SteadyMD | Telehealth infrastructure provider | $25M | Full Confidence | Acquisition Value | Observed | $40M | Partial Confidence |
| 82 | AristaMD | Specialist electronic consultations | $18M–$30M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $62M | Partial Confidence |
| 83 | Avail Medsystems | Procedural telemedicine platform | $5M–$20M | Low Confidence | Acquisition Value | Estimated | $125M | Strong Confidence |
| 84 | Babylon Health | AI-powered virtual care | $8M–$10M | Strong Confidence | Acquisition Value | Observed | $865M | Partial Confidence |
Key valuation trends in the telemedicine market
Insights
- The ten largest telemedicine companies capture about 56% of the dataset’s total midpoint valuation, showing that market value remains concentrated despite the large number of specialized providers.
- Hims & Hers represents about 12% of the full telemedicine valuation pool and is valued at almost 30 times the market median, underlining the strength of scaled consumer distribution.
- Hims & Hers, Lyra Health, and Sword Health account for approximately $17.4 billion in combined value, making three category leaders responsible for more than one-quarter of the full ranking.
- Hims & Hers, Teladoc Health, and Talkspace hold approximately $10.6 billion in combined public market value, but Hims & Hers accounts for more than three-quarters of that amount.
- Lyra Health and Sword Health have raised about $1.3 billion combined while supporting roughly $9.3 billion in midpoint valuation, a blended valuation-to-capital ratio above seven times.
- PlushCare produced the strongest observed acquisition multiple in this group, with a $450 million transaction value equal to roughly 14.5 times its disclosed funding.
- Cadence and Midi Health are worth a combined $2.2 billion after raising $493 million, showing that focused virtual care models can still attract substantial valuations.
- Mental health remains one of the telemedicine market’s largest specialist categories, with Lyra Health, Talkspace, Tava Health, and Boulder Care representing roughly $6.7 billion in combined value.
- Acquisition outcomes vary sharply across telemedicine companies. Eucalyptus achieved a value equal to about ten times disclosed funding, while Thirty Madison reached only about 2.4 times.
- Babylon Health illustrates the market’s downside risk. The company raised approximately $865 million but later recorded an acquisition value of only $8 million to $10 million.
A few word about our methodology
As you can see, we built a database that ranks startups in the telemedicine market based on their current valuation.
Estimating telemedicine startup valuations is not always straightforward. Many private digital health companies do not disclose their valuation, and the available evidence can differ widely by company, geography, and business model.
To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.
Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed telemedicine companies, and official acquisition prices.
When a telemedicine company is publicly listed, we use its current market capitalization as the reference valuation.
If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.
When a telemedicine startup recently raised capital but did not disclose its valuation, we estimate the implied valuation using typical dilution levels for that funding stage.
In some cases, we estimate valuations using operating metrics such as revenue, ARR, patient volume, covered lives, employer contracts, or healthcare provider relationships. We combine these metrics with valuation multiples from comparable digital health companies.
When direct financial data is unavailable, we may use carefully selected comparable startups and signals such as hiring growth, investor quality, geographic expansion, clinical partnerships, reimbursement coverage, or product traction.
All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by public market information, acquisition prices, strong operating metrics, and comparable company analysis.
We also evaluate the age of every data point. Recent information carries more weight, while older funding valuations are treated cautiously and adjusted conservatively when necessary.
This is particularly important in the telemedicine market because public valuations, reimbursement conditions, patient demand, and investor sentiment can change quickly.
Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.
Because valuation data is not always fully public, each telemedicine startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.
Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.
When confidence is lower, we take a more conservative approach by widening the valuation range. This reflects the uncertainty and increases the probability that the true valuation falls within the estimated range.
This reflects how we conduct all our research, including the work behind our report covering the telemedicine market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.
Related blog posts
- What are the latest fundraising trends in the telemedicine market?
- Which companies have raised the most funding in the telemedicine market?
- Is fundraising strong in the telemedicine market right now?
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.